Fortress Biotech Inc (FBIO) Upgraded to Buy by Zacks Investment Research


The brokerage presently has a $4.50 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target suggests a potential upside of 16.58% from the company's previous close.



from Biotech News